Aurora Spine (ASG) AI Stock Analysis

• Market Cap: C$27.32M
• Dividend Yield: N/A
• Average Volume (3M): 10.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: 18.97%
• EPS Growth: 17.57%
• Country: CA
• Employees: 13
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 78,054,950
• 10 Day Avg. Volume: 12,661
• 30 Day Avg. Volume: 10,917
• PEG Ratio: 1.52
• Price to Book (P/B): 4.39
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 73.05
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 0.31
• Enterprise Value/Gross Profit: 2.00
• Enterprise Value/Ebitda: 21.71
• 1Y Price Target: C$0.50
• Price Target Upside: 42.86% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 61 Neutral
• Price Target: C$0.50 ▲(42.86%Upside)

Aurora Spine's overall score is driven by positive corporate events, which highlight strategic growth initiatives and innovative product launches. However, financial performance challenges, such as profitability issues and high leverage, temper the overall outlook. Technical indicators suggest stability but lack strong momentum, while valuation metrics are hindered by negative earnings.

Aurora Spine Business Overview & Revenue Model

Company Description

Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTRA, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases; and Ti-Coated polyether ether ketone interbody cages, which provide spacing and stability between the vertebrae while bone grows to complete the fusion process. It also provides sterile-packed titanium plasma spray coated spinal infusion implants for bone growth, as well as interbody products, such as EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar section of the spine, and discovery for cervical procedures. In addition, the company provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device, which is an integrated plate and spacer system that helps to preserve the natural anatomic profile while providing spinal column support and stability; and SiLo, a posterior fusion device for the sacroiliac joint. Further, it offers DEXA-C, a cervical interbody system, which is a porous 3D-printed intervertebral body fusion device that incorporates low-, mid-, or high-density lattice pattern options to support the matching of patients' bone quality. Aurora Spine Corporation was incorporated in 2013 and is headquartered in Toronto, Canada.

How the Company Makes Money

Aurora Spine makes money through the sale of its medical device products to hospitals, surgical centers, and healthcare providers. The company's revenue model relies on the direct sales of its spinal fusion devices, proprietary surgical tools, and pain management products. Additionally, Aurora Spine may engage in strategic partnerships with healthcare institutions and distributors to expand its market reach and enhance product distribution. The company invests in research and development to continuously innovate and meet the evolving needs of the spinal surgery market, thereby potentially increasing its revenue streams.

Aurora Spine Financial Statement Overview

Summary

Aurora Spine demonstrates revenue growth and good operational efficiency with a healthy gross profit margin of 59.62%. However, challenges in profitability, indicated by a negative net profit margin of -6.04% and high leverage with a debt-to-equity ratio of 0.89, highlight financial risks. The cash flow statement shows positive operating cash flow but negative free cash flow growth, indicating stress in covering capital expenditures.

Income Statement

Aurora Spine's revenue shows a positive growth trend with a decent revenue growth rate of 2.29% over the TTM (Trailing-Twelve-Months) compared to the previous year. However, the company faces challenges in profitability, with a negative net profit margin of -6.04% and a negative EBIT margin of -4.03%. The gross profit margin remains healthy at 59.62%, indicating good operational efficiency.

Balance Sheet

The balance sheet reflects a moderate financial position. The debt-to-equity ratio is relatively high at 0.89, indicating significant leverage and potential financial risk. The equity ratio stands at 35.12%, suggesting a stable equity base but room for improvement. Return on equity is currently negative, reflecting ongoing net losses.

Cash Flow

Aurora Spine's cash flow statement exhibits some positive aspects, such as a positive operating cash flow to net income ratio of 0.80, indicating good cash generation relative to reported losses. However, the free cash flow growth rate is negative at -6.51%, and the free cash flow to net income ratio is also low, pointing to challenges in generating excess cash after capital expenditures.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.56M	14.52M	14.88M	10.54M	8.65M
Gross Profit	10.63M	8.21M	7.81M	4.83M	3.47M
EBITDA	179.90K	-446.20K	-469.27K	-1.90M	-573.86K
Net Income	-1.00M	-1.68M	-1.50M	-2.36M	-232.09K
Balance Sheet
Total Assets	11.67M	11.99M	10.12M	10.56M	7.16M
Cash, Cash Equivalents and Short-Term Investments	775.62K	766.83K	423.40K	3.17M	1.71M
Total Debt	3.67M	3.65M	2.97M	2.38M	2.34M
Total Liabilities	7.28M	6.69M	5.81M	4.99M	3.87M
Stockholders Equity	4.40M	5.30M	4.32M	5.57M	3.28M
Cash Flow
Free Cash Flow	266.47K	-1.41M	-2.43M	-2.85M	-245.07K
Operating Cash Flow	904.33K	-935.06K	-1.56M	-2.13M	309.57K
Investing Cash Flow	-484.32K	-479.13K	-873.21K	-720.61K	-554.64K
Financing Cash Flow	-361.22K	1.76M	-318.15K	4.31M	1.51M

Aurora Spine Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ASG, the sentiment is Positive. The current price of 0.35 is above the 20-day moving average (MA) of 0.32, above the 50-day MA of 0.31, and below the 200-day MA of 0.36, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 67.84 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ASG.

Aurora Spine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QIPT	75 Outperform	C$132.50M	―	-8.34%	―	0.69%	-95.27%
ASG	61 Neutral	C$27.32M	―	-23.87%	―	18.97%	17.57%
PRN	54 Neutral	C$240.43M	―	-66.14%	―	51.21%	15.33%
Sector *	52 Neutral	$7.46B	-0.04	-63.82%	2.49%	16.43%	<0.01%
PINK	49 Neutral	C$25.23M	―	-163.62%	―	245.01%	-4.91%
TLT	48 Neutral	C$50.16M	―	-291.48%	―	-8.63%	7.04%
VPT	44 Neutral	C$24.21M	―	207.08%	―	280.56%	-7.28%

Aurora Spine Corporate Events

Aurora Spine to Showcase Innovations at ASPN Conference

Aurora Spine announced its participation in the 7th Annual American Society of Pain & Neuroscience Conference, where it will showcase its ZIP product series and introduce the AERO Lumbar Fusion System. The company’s involvement, including a podium talk on its novel interspinous fusion device, highlights its commitment to innovation and positions it prominently within the industry, potentially impacting its market presence and stakeholder interests.

Aurora Spine Launches AERO Lumbar Fusion System with Initial Surgeries

Aurora Spine has announced the initial surgeries using its new AERO Lumbar Fusion System, a minimally invasive device designed for patients with facet joint-related pain or instability. The system has received positive feedback from surgeons and is expected to drive significant growth for the company, aligning with its commitment to advancing patient-first, surgeon-friendly innovations.

Aurora Spine Celebrates Milestone with DEXA-C System and Prepares for New Product Launch

Aurora Spine has achieved a significant milestone with its DEXA-C system, having been used in over 1,500 cervical spine surgeries across the United States. This accomplishment highlights the growing adoption and effectiveness of their DEXA Technology, which is designed to match patient bone density and improve surgical outcomes. The company is preparing to launch a new product, the DEXA-L, in Q4 2025, which will expand their portfolio and further address the challenges of spinal fusion in patients with low bone density. This advancement positions Aurora Spine as a leader in patient-matched spinal care, offering innovative solutions for diverse patient needs.

Aurora Spine Achieves Milestone with SiLO™ System in Over 2,500 Procedures

Aurora Spine has achieved a significant milestone with its SiLO™ Sacroiliac Joint Fusion System, which has been used in over 2,500 procedures across the United States. This accomplishment highlights the growing adoption of their minimally invasive technology, which is designed to improve patient outcomes and recovery times. The company’s continued innovation and expansion in the U.S. market, along with positive feedback from the surgical community, underscore its leadership in the field of spinal solutions.

Aurora Spine to Engage Investors at Lytham Partners Spring 2025 Conference

Aurora Spine Corporation announced its participation in the Lytham Partners Spring 2025 Investor Conference, where it will present a webcast and host one-on-one meetings with investors. This participation underscores Aurora Spine’s commitment to engaging with investors and stakeholders, potentially enhancing its market presence and investor relations.

Aurora Spine Reports Record Q1 2025 Financial Results and Strategic Growth Initiatives

Aurora Spine Corporation announced record financial results for the first quarter of 2025, with a 10% increase in revenue compared to the previous year. The company received FDA clearance for its AERO Facet Fusion System and reported significant sales growth in its DEXA-C cervical implant. Aurora Spine is optimistic about future growth, driven by its robust R&D efforts and upcoming product launches, including the DEXA-L series and the AERO system, which are expected to enhance patient outcomes and expand market reach.

Aurora Spine to Announce Q1 2025 Financial Results

Aurora Spine Corporation announced the release schedule for its first quarter fiscal 2025 financial results, which will be filed on May 21, 2025, with a press release and investor conference call to follow on May 22, 2025. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.

Aurora Spine Reports Record Revenue and Positive EBITDAC for FY 2024

Aurora Spine Corporation reported a record revenue of $17.6 million for fiscal year 2024, marking a 21% increase from the previous year. The company’s financial success was driven by a 135% surge in sales of the SiLO-TFX SI joint implant, expansion of its internal sales force, and increased margins. The company also achieved its first annual positive EBITDAC and is poised for further growth with the recent FDA clearance of its new AERO product platform.

Aurora Spine to Release Q4 and Fiscal 2024 Financial Results

Aurora Spine Corporation announced the release of its fourth quarter and fiscal year 2024 financial results, scheduled for April 28, 2025. The company also clarified an error in its management information circulars regarding its stock option plan, ensuring the correct version will be included in future shareholder meeting materials.